Scope
This is NICE guideline NG28, Type 2 diabetes in adults: management, in its 2026 update. The document defines the GLP-1 receptor agonist class scope as at February 2026. It covers individualised care, education, dietary advice, HbA1c measurement and targets, and capillary and continuous glucose monitoring. Initial medicine choice is stratified by comorbidity: no relevant comorbidity, heart failure, atherosclerotic cardiovascular disease, early onset disease, obesity, chronic kidney disease and frailty. The guideline also addresses stepwise introduction of medicines, SGLT-2 inhibitor ketoacidosis precautions, sick day rules, medicine review, further medicines, insulin-based treatment and selected complications. It positions SGLT-2 inhibitors and GLP-1 receptor agonists as much for cardiovascular and renal protection as for glycaemic control.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
HbA1c targets and glucose monitoring
- Check HbA1c every 3 to 6 months, tailored to the individual, until it is stable on unchanged therapy. Once HbA1c and glucose-lowering treatment are stable, check it every 6 months. [1]
- Agree an individual HbA1c target with each person. - Managed by healthy living and diet, alone or with an initial regimen not associated with hypoglycaemia: support an aim of 48 mmol/mol (6.5%). - On a medicine associated with hypoglycaemia: support an aim of 53 mmol/mol (7.0%). If the initial regimen does not give adequate control and HbA1c rises to 58 mmol/mol (7.5%) or higher, take three steps: reinforce diet, healthy living and adherence advice; support an aim of 53 mmol/mol (7.0%); and intensify medicines. [1]
- Consider relaxing the target case by case and in discussion with the person, with particular attention to older or frailer people. This applies if any of the following is present: - longer-term benefit is unlikely, such as reduced life expectancy - hypoglycaemia would be high-risk, such as falls risk, impaired hypoglycaemia awareness, or driving or operating machinery for work - significant comorbidities make intensive management inappropriate [1]
- Do not routinely offer capillary glucose self-monitoring unless one of the following applies: - the person uses insulin - there is evidence of hypoglycaemic episodes - the person takes oral medication that may raise hypoglycaemia risk while driving or operating machinery - the person is pregnant or planning pregnancy Short-term self-monitoring may also be considered when starting oral or intravenous corticosteroids, or to confirm suspected hypoglycaemia. [1]
- Offer isCGM (flash) to people on multiple daily insulin injections who have any of the following: - recurrent or severe hypoglycaemia - impaired hypoglycaemia awareness - a condition or disability that prevents capillary self-monitoring but who could use an isCGM device (or have it scanned for them) - advice to self-test at least 8 times a day otherwise Also offer isCGM to insulin-treated people who would otherwise need a care worker or healthcare professional to monitor their glucose. rtCGM may be considered instead if it is available at the same or lower cost. [1]
Initial medicines by comorbidity
- Offer modified-release metformin plus an SGLT-2 inhibitor to people with no relevant comorbidity, with heart failure, or living with obesity. If metformin is contraindicated or not tolerated, offer SGLT-2 inhibitor monotherapy. [1]
- In atherosclerotic cardiovascular disease, offer three medicines: modified-release metformin, an SGLT-2 inhibitor, and subcutaneous semaglutide (Ozempic) up to 1 mg once weekly for cardiovascular, renal and glycaemic benefit. If metformin is contraindicated or not tolerated, offer the SGLT-2 inhibitor plus semaglutide. [1]
- Early onset disease is diabetes diagnosed before age 40. In this group, offer modified-release metformin with an SGLT-2 inhibitor, or an SGLT-2 inhibitor if metformin is contraindicated or not tolerated. Consider adding either a GLP-1 receptor agonist (for cardiovascular, renal and glycaemic benefit) or tirzepatide (for glycaemic benefit). [1]
- Initial treatment in chronic kidney disease depends on eGFR: - 30 ml/min/1.73 m2 or more: offer modified-release metformin and an SGLT-2 inhibitor. - 20 to less than 30 ml/min/1.73 m2: offer dapagliflozin or empagliflozin plus a DPP-4 inhibitor. - Less than 20 ml/min/1.73 m2: consider a DPP-4 inhibitor. [1]
- In frailty, offer modified-release metformin. Offer an SGLT-2 inhibitor only if the person's frailty does not put them at risk of adverse events such as volume depletion or hypotension. If metformin is contraindicated or not tolerated, consider SGLT-2 inhibitor monotherapy when frailty does not confer that risk, and DPP-4 inhibitor monotherapy when it does. [1]
- When discussing GLP-1 receptor agonists or tirzepatide with women, trans men and non-binary people of childbearing potential, cover the following: - MHRA guidance on use in pregnancy and breastfeeding - weight loss may improve fertility - effective contraception is required while taking the medicine - if pregnancy is wanted, contraception should continue for a period after stopping [1]
Introducing, safeguarding and reviewing medicines
- Introduce medicines stepwise, checking the tolerability and effectiveness of each. When initial therapy combines metformin with one or more other medicines, follow this sequence: - introduce them one at a time, starting with metformin - start any SGLT-2 inhibitor once metformin is at the maximum tolerated dose - start any GLP-1 receptor agonist or tirzepatide once the SGLT-2 inhibitor is at the maximum tolerated dose [1]
- Before starting an SGLT-2 inhibitor, check for increased DKA risk, such as previous DKA, dehydration or volume-depletion risk, or a very low carbohydrate or ketogenic diet. Address modifiable risks before starting. Advise people taking an SGLT-2 inhibitor that such diets would increase their DKA risk. They should therefore speak with their healthcare professional before starting one, and treatment may need suspending for the duration of the diet. [1]
- Include clear sick day rules in each treatment plan. Depending on the person's needs and medicines, the rules may need to specify: - whether and how medicines should change during illness or surgery - whether any medicines (relevant for metformin and SGLT-2 inhibitors) should be stopped when dehydration, vomiting or diarrhoea is a risk - how to adjust insulin - how to restart medication after recovery Follow MHRA ketone-monitoring advice during SGLT-2 inhibitor interruption. [1]
- Consider continuing SGLT-2 inhibitors for cardiovascular or renal benefit even if glycaemic targets are not reached. Stop GLP-1 receptor agonists or tirzepatide in either of two situations: - the person becomes underweight (BMI less than 18.5 kg/m2) - glycaemic targets are not reached and the drug is not being taken for cardiovascular benefit Do not offer a GLP-1 receptor agonist or tirzepatide together with a DPP-4 inhibitor. [1]
Further medicines when glycaemic targets are not met
- With no relevant comorbidity, offer to add a DPP-4 inhibitor first. If it is contraindicated, not tolerated or not effective, offer a sulfonylurea, pioglitazone or an insulin-based treatment. Heart failure follows the same DPP-4-first approach, but the source notes that pioglitazone is contraindicated in heart failure. [1]
- If atherosclerotic cardiovascular disease develops after initial treatment, offer to add subcutaneous semaglutide (Ozempic) up to 1 mg once a week for cardiovascular and renal benefit. When this group needs further glycaemic control, offer to add a sulfonylurea, pioglitazone or an insulin-based treatment. [1]
- Consider adding a GLP-1 receptor agonist or tirzepatide in two groups: - people with early onset disease who need further medicines - people living with obesity who have taken initial therapy for at least 3 months, need further medicines, and are not already taking one of these drugs [1]
- In chronic kidney disease, consider adding a DPP-4 inhibitor. If one is already taken, or it is contraindicated, not tolerated or not effective, consider pioglitazone, an insulin-based treatment, or a sulfonylurea. The sulfonylurea option applies only if eGFR is 30 ml/min/1.73 m2 or more. [1]
- In frailty, when further medicines are needed for hyperglycaemia symptoms and glycaemic targets, consider adding a DPP-4 inhibitor. If one is already taken, or it is contraindicated, not tolerated or not effective, consider adding pioglitazone, a sulfonylurea or an insulin-based treatment. When choosing, weigh the hypoglycaemia and falls risk with sulfonylureas and insulin. [1]
Insulin-based treatment
- When insulin starts: - provide structured education, including injection-site rotation and hypoglycaemia management - continue metformin if it is already taken - stop other medicines used solely for hyperglycaemia - discuss whether to continue medicines used for other benefits, such as cardiovascular protection or weight management [1]
- Offer once- or twice-daily basal insulin as initial insulin therapy. Consider combining it with short or rapid acting insulin, given separately or as a pre-mixed preparation, especially when HbA1c is 75 mmol/mol (9.0%) or higher. When multiple basal insulin types (including biosimilars) and regimens are equally suitable, use the least expensive. [1]
Complications and cardiovascular prevention
- Refer people to local eye screening immediately at diagnosis. Arrange emergency ophthalmology review for any of the following: - sudden visual loss - rubeosis iridis - pre-retinal or vitreous haemorrhage - retinal detachment [1]
- Do not offer antiplatelet therapy (aspirin or clopidogrel) to people without cardiovascular disease. [1]
Limitations and use
- The guideline covers adults with type 2 diabetes only. Several topics are deferred to other NICE guidelines: pregnancy targets and monitoring, hypertension, obesity drug treatment and bariatric surgery, wider chronic kidney disease management, foot problems, neuropathic pain, retinopathy management and insulin delivery.
- At publication, the GLP-1 receptor agonist class is limited to liraglutide, dulaglutide and semaglutide, with subcutaneous semaglutide covered only up to 1 mg weekly. Individual summaries of product characteristics must be checked, especially for renal impairment and pregnancy.
- Research recommendations and later update sections are not included. The visual summary and flowcharts require the original pages.
- Some recommendations are not summarised here. These include education programme standards, detailed dietary advice, CGM support and review, gastroparesis, autonomic neuropathy, erectile dysfunction, periodontitis, insulin reviews and biosimilar switching.
- The recommendations refer to UK-specific bodies and services, including the MHRA, DVLA and NHS programmes.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Type 2 diabetes in adults: management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 2 December 2015
- Publisher’s latest update
- 18 February 2026
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: type 2 diabetes in adults nice
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.